Actovegin solution for injection 400mg 10ml x 5 ampoules — Made in Ukraine — Free Delivery

Pharmacodynamics. The preparation actovegin is a deproteinized hemoderivative from the blood of calves, containing only physiological substances with a molecular weight of 5000 da.

The preparation Actovegin is characterized by three main effects: metabolic, neuroprotective and microcirculatory. Inositol phosphate oligosaccharides (IPO), which are part of Actovegin, are responsible for improving the utilization and absorption of oxygen, as well as for improving energy metabolism and glucose uptake. This action has the potential to be beneficial after injury or damage to tissues and organs, in particular the brain, and to reduce the formation of lactate.

Several pathways have been identified by which the neuroprotective mechanism of action of the preparation Actovegin is carried out, due to the effect on the structure of beta-amyloid peptides (Aβ25–35), which induce apoptosis. Beta-amyloid peptides act as triggers in a number of molecular and cellular processes, including oxidative stress and inflammation, resulting in neuronal death, which in turn leads to impaired memory and cognitive functions.

Nuclear factor kappa B (NF-kB) performs numerous functions in the processes of both the central and peripheral nervous systems. It regulates the process of inflammation, which worsens the course of degenerative and vascular disorders, and is a factor involved in the formation of pain, learning, memory and neuroprotection.

Actovegin activates the NF-kB expression reporter gene in a dose-dependent manner, and this transient activation may at least partially explain the neuroprotective properties of Actovegin.

Another important mechanism of action of Actovegin is associated with the nuclear enzyme poly (ADP-ribose) -polymerase (PARP). PARP plays an important role in detecting single-stranded DNA breaks and in the repair process, however, excessive activation of this enzyme can trigger processes in the cell that lead to the completion of oxidative metabolism. These processes can ultimately lead to cell death due to depletion of energy reserves. It was revealed that Actovegin reduces the activity of PARP, which improves the functioning and optimizes the morphological structure of the central and peripheral nervous system.

The positive effect of the preparation Actovegin on microcirculation is due to its effects such as an increase in the blood flow rate in the capillaries, a decrease in the pericapillary zone and a decrease in the smooth muscle tone of the precapillary arterioles and capillary sphincters, a decrease in arterio-venular shunting of blood with an increase in blood flow in the capillary bed and an increase in the function of the endothelial endothelialis. channel.

Disorders of cerebral circulation, including post-stroke cognitive impairment and dementia. Actovegin has been shown to be beneficial in the symptomatic treatment of dementia and dementia-related conditions in over 450 patients in several small randomized clinical trials. Demonstrated efficacy compared with placebo on endpoints related to cognitive function, daily activity and overall clinical response, while statistically significant improvement in the speed of cognitive processes was not found.

In a 12-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Actovegin in patients with post-stroke cognitive impairment was compared with placebo. 503 patients (250 patients received Actovegin) were randomized between the 5th and 7th days after the onset of ischemic stroke. The 6-month treatment period consisted of ≤20 infusions (2000 mg daily), followed by taking the preparation in the form of tablets (2 tablets 200 mg 3 times a day), after which a 6-month observation treatment was carried out, during which the patients were kept in accordance with with standard clinical practice. At 6 and 12 months, patients treated with Actovegin showed statistically significant changes in the number of points on the extended cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog +) and on the Montreal Cognitive Assessment Scale (MoCA) compared with patients who received a placebo. At the 3rd, 6th and 12th months, most of the patients in the group receiving Actovegin showed a response to treatment according to the ADAS-cog + scale. The incidence of serious adverse events and deaths was similar in both treatment groups.